Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519662 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
A Phase 1 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00519662: Completed Phase 1 study, sponsored by Sunesis Pharmaceuticals.
NCT00519662 is a Phase 1 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00519662, a Phase 1 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.
Interventions
- DRUG SNS-314
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
What the finished NCT00519662 record still lists
NCT00519662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which SNS-314 is the first listed.
NCT00519662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00519662 about?
NCT00519662 is a clinical study titled "Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors". This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.
What is the current status of trial NCT00519662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2007-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00519662?
The interventions under investigation include: SNS-314 (DRUG).
Who is sponsoring clinical trial NCT00519662?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00519662's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia